Science

13126 readers

3 users here now

Studies, research findings, and interesting tidbits from the ever-expanding scientific world.

Subcommunities on Beehaw:

Space

Be sure to also check out these other Fediverse science communities:

This community's icon was made by Aaron Schneider, under the CC-BY-NC-SA 4.0 license.

founded 3 years ago

MODERATORS

[email protected]

US drug agency approves potent painkiller — the first non-opioid in decades (www.nature.com)

submitted 5 days ago by [email protected] to c/[email protected]

8 comments fedilink hide all child comments

Now, millions more people will soon have access to this painkiller — a drug called suzetrigine that works by selectively blocking sodium channels on pain-sensing nerve cells and delivers opioid-level pain suppression without the risks of addiction, sedation or overdose. On Thursday, the US Food and Drug Administration approved suzetrigine for short-term pain management, making it the first pain drug given a regulatory nod in more than 20 years that works through a brand-new mechanism.

"This is a big step forward," says Stephen Waxman, a neuroscientist at the Yale School of Medicine in New Haven, Connecticut.

"Anything we can add to the toolbox that will allow us to reduce opioid dependency is a significant positive," says Paul White, an anaesthesiologist at the Cedars-Sinai Medical Center in Los Angeles, California, who was involved in suzetrigine's development.

top 8 comments

sorted by: hot top controversial new old

[–] [email protected] 19 points 5 days ago (1 children)

Any move away from opiods is a great step for medicine. Not just in that they are addictive, but also that they do not work on a sub-set of the population.

[–] [email protected] 8 points 5 days ago (1 children)

I'm always slightly leary of channel blockers. But if it was just approved, that means it's been going through trials and reviews for several years. I'm assuming that this has passed rigorous review for safety and efficacy, so I'm cautiously optimistic that this will be a great tool and not found to be a horrible drug five years down the road.

[–] [email protected] 4 points 5 days ago (1 children)

what's the concern with channel blockers? /genq

[–] [email protected] 11 points 4 days ago (1 children)

Most everything in the body is controlled by ion channels in cells. Channel blockers (sodium and calcium are the main ones) tend to have a narrow dose range and numerous side effects. If this novel drug really is selective, then the side effects may be reduced.

[–] [email protected] 2 points 2 days ago

I see, thank you for explaining!

[–] [email protected] 12 points 5 days ago

without the risks of addiction

Didn't the drug companies say opioids weren't addictive? I guess we're up for round 2 ....

Edit: from the company's press release:

Vertex has established a wholesale acquisition cost for JOURNAVX in the United States of $15.50 per 50mg pill.

That's the wholesale price. Consumer price will be higher.

The prescribing information sheet says to start with 100mg, then take 50mg every 12 hours. So at wholesale costs, a two-week supply is $450; actual patient costs will be higher. Also, I limited my math to only two weeks because:

Use JOURNAVX for the shortest duration, consistent with individual patient treatment goals. Use of JOURNAVX for the treatment of acute pain has not been studied beyond 14 days.

[–] LoganNineFingers 5 points 4 days ago

As someone in the middle of the show "Dopesick" I'll take a pass on this one for a bit

[–] [email protected] 3 points 4 days ago

Archive link:

https://archive.is/RUB7x